Invasive mucormycosis during treatment for acute lymphoblastic leukaemia—successful management of two life-threatening diseases

A 5-year-old patient treated for acute lymphoblastic leukaemia (ALL) developed proven pulmonary invasive fungal disease (IFD) due to Actinomucor elegans. While completing ALL treatment according to AIEOP ALL protocol 2009 for further 15 months, antifungal treatment with liposomal amphotericin B and...

Descripción completa

Detalles Bibliográficos
Autores principales: Trobisch, Andreas, Marterer, R., Gorkiewicz, G., Flaschberger, S., Lackner, H., Seidel, M., Sperl, D., Karastaneva, A., Kohlmaier, B., Egger, M., Urban, C., Benesch, M., Strenger, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083803/
https://www.ncbi.nlm.nih.gov/pubmed/31410599
http://dx.doi.org/10.1007/s00520-019-04962-3
Descripción
Sumario:A 5-year-old patient treated for acute lymphoblastic leukaemia (ALL) developed proven pulmonary invasive fungal disease (IFD) due to Actinomucor elegans. While completing ALL treatment according to AIEOP ALL protocol 2009 for further 15 months, antifungal treatment with liposomal amphotericin B and intermittent additional posaconazole was continued until immune reconstitution 7 months after the end of ALL treatment. Repeated imaging guided treatment decisions. Twenty-six and 19 months after the end of ALL treatment and antifungal treatment, respectively, the patient is still in the first complete remission and shows no signs of active invasive fungal disease (IFD).

Ejemplares similares